Piper Sandler cuts Myriad Genetics stock rating on profit concerns

Piper Sandler downgraded Myriad Genetics (MYGN) to Underweight and cut its price target to $2.00 from $5.45 after concluding the business model cannot reach profitability via growth or cost cuts. The stock has fallen 47.6% YTD and the firm flagged structural challenges, citing negative LTM EBITDA of -$40.3M and a loss of $1.20/share. Q2 FY2026 revenue of $190.7M declined 11% YoY and missed expectations by ~$15.3M (7.4%), while the adjusted loss of $0.25/share widened vs the Street’s -$0.06.

Analysis

This is less a one-quarter earnings miss than a capital-allocation failure in a high-fixed-cost diagnostics model. When a small-cap genomics platform cannot convert scale into operating leverage, the market usually moves from valuing growth to valuing survival: lower terminal margins, higher dilution probability, and a wider gap versus better-capitalized peers. The relative winners are the companies with either stronger balance sheets or more defensible recurring demand, while weaker single-platform names can see multiple compression even if their top line merely stagnates.

The near-term setup is still negative over days to weeks because sell-side models will likely reset lower again before the next print, and that tends to pressure a small float name disproportionately. Over 1-3 months, the key catalyst is not another quarter of bad numbers but whether management signals a credible monetization path for assets or instead resorts to financing to extend runway. If the business keeps consuming cash at the current pace, equity dilution becomes the main economic story, not operating turnaround.

The contrarian risk is that the stock may already be pricing a large amount of distress, so the easy money on the short side is in the first reflexive leg lower. But the prior decision not to pursue divestitures meaningfully reduces confidence in a clean asset-sale floor, so the burden of proof is on management to show sequential improvement in margins or cash burn. If they cannot, the setup stays structurally negative for 6-18 months, with downside driven by dilution or a prolonged low-multiple drift rather than one dramatic event.

Key Decisions for Investors

• Short MYGN on any post-downgrade bounce; use a 1-3 month horizon and prefer put spreads if borrow is tight. Risk/reward favors another leg lower if the next company update does not show sequential stabilization.
• Pair trade: long NTRA vs short MYGN to isolate execution quality and balance-sheet differentiation in genetic testing. This is the cleaner expression than a broad sector short.
• Set an alert for MYGN cash burn and any language change around asset sales or financing at the next update. Falsifier for the short thesis: two consecutive quarters of improving sequential revenue plus EBITDA inflection.
• If seeking lower-risk expression, buy MYGN downside via 3-6 month put spreads rather than outright puts; the name is small-cap and can overshoot on any rumor of strategic action.
• Avoid initiating long exposure until there is evidence the business can self-fund operations; absent that, any rally is likely a short-covering event rather than a durable rerating.